Tuesday, April 7, 2015 | 8:30 AM - 5:00 PM
Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School, Boston, MA)
Speakers: Renier J. Brentjens (Memorial Sloan Kettering Cancer Center), Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle, MA), Jerome Ritz (Harvard Medical School), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology, Cambridge, MA)
Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.
Monday, April 27, 2015 | 8:30 AM - 4:15 PM
Speakers: Erwan Bezard (University of Bordeaux),
Patrick Brundin (Van Andel Institute), Anna Sauerbier (NPF Parkinson's International Centre of Excellence, Kings College London), Marie-Francoise Chesselet (David Geffen School of Medicine at UCLA), Maurizio Facheris (Michael J. Fox Foundation for Parkinson's Research), Horacio Kaufmann (NYU Langone Medical Center), Olivier Rascol (Toulouse University Hospital), Daniel Weintraub (University of Pennsylvania)
This symposium will review clinical tools for the diagnosis and treatment of non-motor symptoms of Parkinson's disease, discuss the disease mechanisms, and address preclinical models for the development of new therapeutics.
Thursday, May 21, 2015 | 9:00 AM - 5:00 PM
Speakers: Rolf Brekken (University of Texas, Southwestern), Stephen J. Forman (City of Hope), Thomas F. Gajewski (The University of Chicago Medicine), Carl June (University of Pennsylvania), David Kaufman (Merck Research Laboratories), Mark R. Litzow (Mayo Clinic), Andy Minn (University of Pennsylvania), Elaine Pinheiro (Merck Research Laboratories), Robert Vonderheide (University of Pennsylvania)
This symposium will bring together leading experts in immunotherapy and immunology to discuss these emerging approaches, along with the challenges and opportunities faced in this evolving field.
Tuesday, May 26, 2015 | 8:30 AM - 4:30 PM
Speakers: Richard Allen (Pfizer), John Burke (Applied BioMath), Nitin Mehrotra (US Food and Drug Administration), Tim Rolph (Pfizer), Vikram Sinha (US Food and Drug Administration), Peter Sorger (Harvard Medical School), Paul Watkins (Hamner-UNC Institute for Drug Safety Sciences)
Quantitative Systems Pharmacology (QSP) has been used successfully in drug discovery and development, yet lacks industry-wide adoption. This symposium highlights past successes and future challenges of using QSP in preclinical and clinical research.
Thursday, May 28, 2015 | 8:00 AM - 3:00 PM
Keynote Speaker: Craig Thompson (Memorial Sloan-Kettering Cancer Center)
Speakers: John Blenis (Weill Cornell Medical College ), Lydia Finley (Memorial Sloan-Kettering Cancer Center), Alec Kimmelman (Harvard Medical School), Christian M. Metallo (University of California, San Diego ), Elena Piskounova (University of Texas, Southwestern ), Sohail Tavazoie (The Rockefeller University )
This symposium will highlight insights into tumor metabolism from leaders in the field and explore how this information is being used to design safe and effective, metabolism-targeted therapies.
Tuesday, March 24, 2015 | 11:45 AM - 4:00 PM
Speakers: P. Jeffrey Conn (Vanderbilt University), Ron Dror (Stanford University), Christopher Fotsch (Amgen), Corey Hopkins (Vanderbilt University), Whitney Nolte (Pfizer)
In this symposium, academic and industry scientists will describe the identification, characterization, and development of PAMs for challenging GPCRs.
Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM
Speakers: Chad Cowan (Harvard University), James Inglese (National Center for Advancing Translational Sciences, NIH), J. Keith Joung (Massachusetts General Hospital), Randall Platt (Massachusetts Institute of Technology), Yi Yang (Novartis Institutes for Biomedical Research), Lei (Stanley) Qi (University of California San Francisco)
The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.
Wednesday, January 21, 2015 | 8:30 AM - 4:00 PM
Speakers: Jasna Brujic (New York University), Bridget Carragher, John Chodera, Oliver Clarke, Erik Debler, Nancy Greenbaum, David Hall, Barry Honig, Jinrang Kim (Columbia University), Nina Liu (Albert Einstein College of Medicine), Patrick Loria (Yale University), Sean McSweeney (Brookhaven National Lab), Clint Potter
The New York Area Structural Biology Discussion Group convenes twice annually and presents talks and poster sessions from graduate students, postdocs, and laboratory heads.
Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM
Speakers: Matthew D. Breyer (Eli Lilly and Company), Frank C. Brosius (University of Michigan Medical School), Benjamin D. Humphreys (Brigham and Women's Hospital), Matthias Meier (F. Hoffmann-La Roche Ltd), Shahnaz Shahinfar (S. Shahinfar Consulting, Inc. and The Children's Hospital of Philadelphia), Katalin Susztak (University of Pennsylvania), Aliza Thompson (Food and Drug Administration)
Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.
Organizers: Magdalena Alonso-Galicia (MAG Pharma Consulting LLC), Ken Jones (Allergan), Scott MacDonnell (Boehringer Ingelheim Pharmaceuticals), and Jennifer Henry (formerly at The New York Academy of Sciences)
This eBriefing reviews targets for preventive or therapeutic interventions in diabetic kidney disease and discusses clinical development.
Organizers: Cynthia Duggan (The New York Academy of Sciences), Maike Stenull (Johnson & Johnson), and George Vradenburg (Global CEO Initiative on Alzheimer's Disease)
Keynote Speaker: Dennis Gillings (World Dementia Council)
This eBriefing explores new public and private funding mechanisms to meet the challenges of financing AD research and care.
Keynote Speaker: The Honorable Patrick J. Kennedy (Former U.S. Representative, Rhode Island; One Mind for Research; Kennedy Forum)
This eBriefing explores the translation of neuroscience breakthroughs into therapies for mental illness. A keynote lecture looks at strategies to dispel stigma surrounding mental illness so that new treatments are accessible to all.
Organizers: Peng Wu (Albert Einstein College of Medicine) and Jennifer Henry (formerly at The New York Academy of Sciences)
Keynote Speakers: Jim Paulson (Scripps Research Institute) and K. Barry Sharpless (Scripps Research Institute)
This eBriefing explores recent developments in the search for click reactions with applications in disease diagnosis and therapy.
Delve into the world of prebiotic and probiotic science. We talk to three people in the field and learn why keeping the good microbes in our bodies happy means a lot for health.
Researchers at Harvard have discovered why the headaches of some migraine sufferers worsen when the person is exposed to light. Rami Burstein, the study's senior author, explains what's happening in the brain, and how they made the breakthrough.
December 18, 2009
We sit down with science photographer Felice Frankel and nanotechnology pioneer and Harvard chemist George Whitesides to hear about their new book on nanoscience, No Small Matter.
Visit the lab of Hunter College's Jill Bargonetti, a biologist researching cancer. Her team studies P53, a natural tumor-suppressor protein found in our bodies with a Dr. Jekyll and Mr. Hyde personality.
February 23, 2010
Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
April 28, 2009
Protein kinases play a key role in almost every major pathway in eukaryotic cells. Structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.